Health-care companies were more or less flat as traders rotated into sectors less sensitive to interest-rate moves.
Danish drug maker Novo Nordisk and Anthropic struck a partnership deal to deploy the Claude AI model with the aim of accelerating the development of new medicines.
British firm Reckitt Benckiser, the maker of Mucinex and Lysol, plans to expand U.S. product development and manufacturing to respond more quickly to shifts in consumer demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.